CRIS Curis, Inc.
0.7366USD-1.66%Mkt Cap: 1.79M $P/E: 0.561d ago
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral s…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap1.79M USD
Enterprise Value-2.46M USD
Revenue (TTM)4.31M USD
Gross Profit9.40M USD
Net Income (TTM)-7.58M USD
Revenue/Share2.21 USD
Last Price0.7366 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.56
P/E (Forward)-0.12
PEG—
EV/EBITDA0.07
EV/Revenue-0.57
P/S0.42
P/B0.31
EPS (TTM)1.27
EPS (Forward)-6.01
52W Range
0.72000% of range34.80
52W High34.80 USD
52W Low0.7200 USD
Profitability
Gross Margin99.52%
Oper. Margin-833.40%
EBITDA Margin0.00%
Profit Margin-80.29%
ROE-138.81%
ROA-37.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.20M USD
CapEx (TTM)—
FCF Margin-365.46%
FCF Yield-882.60%
Net Debt-4.03M USD
Net Debt/EBITDA0.11
Balance Sheet
Debt/Equity0.30
Current Ratio0.49
Quick Ratio0.37
Book Value/Sh2.41 USD
Cash/Share2.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 30, 2018
Splits
Last Split1:20
Split DateJul 6, 2026
Analyst Consensus
Rating—
Target (Mean)42.67 USD
Upside (mean)+5692.4%
Target Range20.00 USD – 65.00 USD
20.00+5692.4% to mean65.00
# Analysts3
Ownership
Shares Out.2.43M
Float1.84M
Insiders6.46%
Institutions29.05%
Short Interest
Short Ratio0.5d
Short % Float2.87%
Short % Out.2.85%
Shares Short69.03K
Short (prev mo.)324.28K
Technical
SMA 501.952 (-62.3%)
SMA 20010.76 (-93.2%)
Beta3.10
S&P 52W Chg16.45%
Avg Vol (30d)165.34K
Avg Vol (10d)202.49K
Technical Indicators
RSI (14)16.8
MACD-0.4330
MACD Signal-0.5333
MACD Hist.+0.1003
BB Upper1.281 USD
BB Middle0.9522 USD
BB Lower0.6236 USD
BB Width69.01%
ATR (14)0.1549 USD
Vol Ratio (20d)0.69x